masshealth glp-1 coverage 2026 for obesity treatment in 13 US states' Medicaid programs Massachusetts Health Insurance Marketplace: 2026

In light of the above data, the following section will outline clinical recommendations for using GLP-1RAs to treat patients with specific eating disorder diagnoses and a BMI in the range of overweight or obesity

Currently, those with alcohol and substance use disorders (ASUDs) receive behavioural, motivational, and cognitive treatment, but the number of approved medications is somewhat limited

had a run-in period before randomization and withdrew all OADs excluding metformin at the start of the run-in phase ( Table 1 Outlines of the included studies

8.1 Challenges in the optimization of multi-receptor agonists Although multi-receptor agonists such as tirzepatide exhibit enhanced effectiveness, their development poses distinct obstacles that need careful attention

These drugs, GLP-1 receptor agonists, were originally designed to harness the same pathways that naturally produce GLP-1